U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07488065) titled 'A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants' on March 11.
Brief Summary: This is a randomized, double-blind, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SKB575. This study consists of two parts. Phase Ia is a single ascending dose study in healthy subjects and Phase Ib is a proof-of-concept study in patients with moderate to severe atopic dermatitis.
Study Start Date: March 25
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Intervention:
DRUG: SKB575 Injection/SKB575 Placebo
Pharmac...